Greenland Mines Ltd (NASDAQ: GRML)

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. The company operates a generic drug portfolio that includes 5 market approved anti cancer drugs authorized for sale in Germany. These drugs are part of the FOLFOX and FOLFIRI regimens used to treat metastatic colorectal, gastric and lung cancers. Greenland Mines Ltd also holds a biosimilar biologics platform focused on oncology, comprising 2 off patent antibodies obtained from Reliance Life Sciences that serve as alternatives to reference therapeutics such as rituximab, trastuzumab and bevacizumab. In addition, the company maintains a proprietary gene therapy platform that uses the Klotho protein to address neurodegenerative conditions like Alzheimer’s disease and amyotrophic lateral sclerosis. In March 2026, Greenland Mines Ltd completed the acquisition of Greenland Mines Corp., which adds the development and mining of critical and precious minerals to its business activities.

We generate revenue primarily from the sale of its 5 market approved anti cancer drugs in Germany, which are distributed to hospitals and pharmacies for use in chemotherapy regimens. Revenue also comes from the 2 off patent biosimilar antibodies, which are marketed to oncology providers as cost effective alternatives to branded biologics. The gene therapy platform, while still in pre clinical development, is expected to create future revenue through licensing agreements, partnership collaborations, or eventual product sales after regulatory approval. Additionally, the recently acquired mining subsidiary is positioned to generate income from the extraction and sale of critical and precious minerals to industrial customers. The company may also earn royalties from its licensed technologies, including a 3 percent net sales fee on certain gene therapy products under its agreements with the Autonomous University of Barcelona.

In the oncology biosimilars market, Greenland Mines Ltd competes with large generic drug manufacturers such as Pfizer, Mylan, Amgen, Teva Pharmaceutical Industries, Celltrion, Sandoz and other firms that produce biosimilar versions of rituximab, trastuzumab and bevacizumab. The company’s advantage lies in its exclusive licensing agreement with Reliance Life Sciences, which grants access to proprietary manufacturing know how and regulatory data for these biosimilar candidates. In the gene therapy field, the company faces competition from academic groups and biotech firms pursuing neurodegenerative treatments, including Unity Biotechnology, but it holds an exclusive worldwide license from the Autonomous University of Barcelona for the secreted Klotho s KL protein, providing a proprietary edge in Alzheimer’s and ALS therapy development. The mining division, although newly entered, operates in a sector dominated by major multinational miners, yet it seeks to differentiate itself by targeting critical minerals that are essential for high technology and green energy applications.

The company serves hospitals, outpatient oncology clinics, and patients receiving chemotherapy through its generic drug and biosimilar oncology products. Its gene therapy candidates are intended for neurology departments, memory disorder centers and specialized treatment facilities that focus on Alzheimer’s disease and amyotrophic lateral sclerosis. The mining division will supply critical and precious minerals to manufacturers of electronic components, producers of renewable energy equipment and industrial users requiring these materials for production processes.